Day: August 5, 2026

Moderna disclosed that its experimental mRNA norovirus vaccine did not meet the statistical criteria for early success at a planned interim analysis of its phase 3 trial, a setback for what remains the most advanced effort worldwide to prevent a virus that causes an estimated 19 million to 21 million cases of vomiting and diarrhea in the United States each year. The company reported the result …